Lui H, Anderson R R
Department of Medicine, University of British Columbia, Vancouver.
Dermatol Clin. 1993 Jan;11(1):1-13.
The application of PDT in dermatology has been limited by technical problems, lack of standardized treatment parameters and controlled clinical trials, and cutaneous photosensitivity. PDT requires specially trained personnel and relies on devices that are expensive and difficult to maintain. In North America, PDT is currently performed at only a few centers on an investigational basis. Although a great deal of anecdotal clinical information is available on PDT for treating non-melanoma skin cancer, controlled trials are still needed in order to compare PDT with the highly effective methods already available. PDT may also be useful for a variety of nononcologic dermatoses. New photosensitizers such as BPD-MA, NPe6, and ALA offer the promise of causing significantly less prolonged photosensitivity than the currently available agents; combined with well-designed clinical studies, this will undoubtedly facilitate the acceptance of PDT into standard dermatologic practice.
光动力疗法（PDT）在皮肤科的应用受到技术问题、缺乏标准化治疗参数和对照临床试验以及皮肤光敏性的限制。PDT需要经过专门培训的人员，并且依赖于昂贵且难以维护的设备。在北美，目前仅在少数几个中心进行基于研究目的的PDT治疗。尽管有大量关于PDT治疗非黑色素瘤皮肤癌的临床轶事信息，但仍需要进行对照试验，以便将PDT与现有的高效方法进行比较。PDT也可能对多种非肿瘤性皮肤病有用。新型光敏剂如BPD - MA、NPe6和ALA有望产生比现有药物显著更短的光敏持续时间；结合精心设计的临床研究，这无疑将促进PDT被纳入标准皮肤科实践。
